Skip to main content
SICHUAN KELUN PHARMACEUTICAL CO., LTD. logo

SICHUAN KELUN PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 002422 ISIN · CNE100000PW7 LEI · 30030014Z0J8J835FO94 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,676 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002422

About SICHUAN KELUN PHARMACEUTICAL CO., LTD.

https://www.kelun.com

Sichuan Kelun Pharmaceutical Co., Ltd. specializes in the research, development, and large-scale manufacturing of healthcare products. The company is a prominent producer of intravenous (IV) solutions, offering a comprehensive portfolio of large-volume injections in various packaging formats. Its product range includes small-volume injections, tablets, capsules, and powder for injections, addressing therapeutic areas such as anti-infection, parenteral nutrition, and cardiovascular health. The organization maintains a vertically integrated supply chain, encompassing the production of intermediates and active pharmaceutical ingredients (APIs). Through its research divisions, the company focuses on high-end generic drugs and novel therapeutic entities, with significant advancements in antibody-drug conjugates (ADCs) and treatments for oncology and immunology.

Recent filings

Filing Released Lang Actions
关于子公司在2026年美国临床肿瘤学会年会上公布多项创新药物研究成果的公告
Regulatory Filings Classification · 85% confidence The document is an official announcement (“公告”) by Sichuan Kelun Pharmaceutical Co., Ltd. informing the market that its subsidiary will present multiple clinical drug research results at the 2026 ASCO annual meeting. It summarizes clinical trial outcomes for two investigational drugs and provides background on pipeline assets. It contains no financial statements, board changes, earnings data, proxy materials, financing details, or other specialized filings. Therefore, it is a general regulatory announcement and falls under the Regulatory Filings (RNS) category.
2026-05-22 Chinese
关于子公司SKB118新药临床试验申请获国家药品监督管理局批准的公告
Regulatory Filings Classification · 81% confidence The document is a corporate announcement (“公告”) reporting that the company’s subsidiary received NMPA approval for an IND clinical trial. It is a short regulatory disclosure (under 5,000 characters) rather than a full financial report, earnings release, or other specific filing. It does not present financial statements or detailed investor materials. Therefore, it best fits the fallback category for general regulatory announcements: Regulatory Filings (RNS).
2026-05-13 Chinese
关于子公司核心产品TROP2 ADC芦康沙妥珠单抗(sac-TMT)新增适应症上市申请获国家药品监督管理局受理的公告
Regulatory Filings
2026-05-08 Chinese
关于回购公司股份进展的公告
Regulatory Filings
2026-05-06 Chinese
关于开展套期保值业务的可行性分析报告
Capital/Financing Update Classification · 95% confidence The document is a detailed feasibility analysis report regarding the company's plan to engage in hedging activities to manage currency and interest rate risks. It discusses the purpose, scope, scale, risk analysis, and risk control measures related to hedging business. There is no indication that this is an announcement of a report publication, nor is it a certification or a brief summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or legal proceeding. The content is focused on the company's management and risk control of financial derivatives and hedging activities, which aligns with a Capital/Financing Update as it relates to the company's financing risk management strategies and capital risk hedging plans.
2026-04-02 Chinese
第八届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 12th meeting of the 8th Board of Directors of Sichuan Kelun Pharmaceutical Co., Ltd. It includes approvals of various reports such as the 2025 Annual Board Work Report, 2025 Annual General Manager Work Report, 2025 Annual Report, 2025 Financial Statements audited by an accounting firm, internal control self-assessment report, ESG report, profit distribution plan, and other corporate governance matters. The document also mentions that these reports are published on the company's designated disclosure website and in newspapers, indicating that the actual reports are separate documents. The content primarily consists of board meeting resolutions and approvals, including changes to the company charter and capital structure, and plans for the upcoming shareholders' meeting. This type of document is best classified as Board/Management Information (MANG) because it announces board meeting decisions and management reports rather than being the full annual report or financial statements themselves.
2026-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.